Education
About Us
Working with TipRanks
Follow Us
Leap Therapeutics Inc (LPTX)
NASDAQ:LPTX
Total Valuation
Leap Therapeutics has a market cap or net worth of $13.87M. The enterprise value is -$18.69M.
Market Cap$13.87M
Enterprise Value-$18.69M
Share Statistics
Leap Therapeutics has 41,439,530 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,439,530
Owned by Insiders6.11%
Owned by Institutions0.83%
Financial Efficiency
Leap Therapeutics’s return on equity (ROE) is -1.93 and return on invested capital (ROIC) is -200.12%.
Return on Equity (ROE)-1.93
Return on Assets (ROA)-1.38
Return on Invested Capital (ROIC)-200.12%
Return on Capital Employed (ROCE)-2.00
Revenue Per Employee0.00
Profits Per Employee-1.30M
Employee Count52
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio0.66
Price to Fair Value3.09
Price to FCF-0.23
Price to Operating Cash Flow-0.23
PEG Ratio-0.03
Income Statement
In the last 12 months, Leap Therapeutics had revenue of 0.00 and earned -67.56M in profits. Earnings per share was -1.81.
Revenue0.00
Gross Profit0.00
Operating Income-70.06M
Pretax Income-66.97M
Net Income-67.56M
EBITDA-66.97M
Earnings Per Share (EPS)-1.81
Cash Flow
In the last 12 months, operating cash flow was -59.26M and capital expenditures 0.00, giving a free cash flow of -59.26M billion.
Operating Cash Flow-59.26M
Free Cash Flow-59.26M
Free Cash Flow per Share-1.43
Dividends & Yields
Leap Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.94
52-Week Price Change-83.57%
50-Day Moving Average0.36
200-Day Moving Average1.44
Relative Strength Index (RSI)50.61
Average Volume (3m)2.28M
Important Dates
Leap Therapeutics upcoming earnings date is Aug 18, 2025, TBA (Confirmed).
Last Earnings DateMay 13, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Leap Therapeutics as a current ratio of 3.41, with Debt / Equity ratio of 0.74%
Current Ratio3.41
Quick Ratio3.41
Debt to Market Cap<0.01
Net Debt to EBITDA0.70
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Leap Therapeutics has paid 585.00K in taxes.
Income Tax585.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Leap Therapeutics EV to EBITDA ratio is -0.91, with an EV/FCF ratio of -1.01.
EV to Sales0.00
EV to EBITDA-0.91
EV to Free Cash Flow-1.01
EV to Operating Cash Flow-1.01
Balance Sheet
Leap Therapeutics has $32.71M in cash and marketable securities with $154.00K in debt, giving a net cash position of -$32.56M billion.
Cash & Marketable Securities$32.71M
Total Debt$154.00K
Net Cash-$32.56M
Net Cash Per Share-$0.79
Tangible Book Value Per Share$0.93
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Leap Therapeutics is $3.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$3.00
Price Target Upside782.35% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast64.01%